MERIDIAN BIOSCIENCE INC's gross profit margin for the first quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased, representing an increase to the bottom line.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 4.80% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||47.16||48.01|
|Net Income ($mil)||8.89||7.9|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||0.0||49.52|
|Total Assets ($mil)||186.44||177.44|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||66.97||63.8|
|Return on Assets||19.59||19.84|
|Return on Equity||21.67||21.89|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||41.84||41.7|
|Div / share||0.2||0.2|
|Book value / share||4.03||3.86|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||258525.0||225606.0|
BUY. The current P/E ratio indicates a significant discount compared to an average of 55.38 for the Health Care Equipment & Supplies industry and a value on par with the S&P 500 average of 21.13. Conducting a second comparison, its price-to-book ratio of 4.64 indicates a significant premium versus the S&P 500 average of 2.51 and a premium versus the industry average of 4.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. The valuation analysis reveals that, MERIDIAN BIOSCIENCE INC seems to be trading at a discount to investment alternatives within the industry.
|VIVO 21.51||Peers 55.38||VIVO NA||Peers 26.18|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
VIVO is trading at a significant discount to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|VIVO 20.34||Peers 21.07||VIVO 4.58||Peers 1.67|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
VIVO is trading at a valuation on par with its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
VIVO trades at a significant premium to its peers.
|VIVO 4.64||Peers 4.14||VIVO 3.57||Peers -9.76|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
VIVO is trading at a premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
VIVO is expected to have an earnings growth rate that significantly exceeds its peers.
|VIVO 4.04||Peers 5.78||VIVO 1.00||Peers 18.99|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
VIVO is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
VIVO significantly trails its peers on the basis of sales growth
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.